latest news releases from the newsroom
Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation to Initiate Physical Testing of a Proprietary Method to Produce Major Medical Isotope Mo-99
KENNEWICK, Wash., June 12, 2009 (GLOBE NEWSWIRE) -- Advanced Medical Isotope Corporation ("AMIC") (Pink Sheets:ADMD) (http:www.isotopeworld.com), a company engaged in the production and distribution of medical isotopes, Along with a senior industrial partner and the University of Missouri (MU) are collectively collaborating and preparing to test and develop prototype compact devices to produce radioisotopes which could supply clinical quantities of Mo-99 within a few years.
Momenta Pharmaceuticals Announces Appointment of Bruce L. Downey to Board of Directors
CAMBRIDGE, Mass., June 12, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced the appointment of Bruce L. Downey to its Board of Directors, effective June 11, 2009. Mr. Downey is the former Chairman and Chief Executive Officer of Barr Pharmaceuticals, Inc. and a former Chairman of the Generic Pharmaceutical Association (GPhA). He succeeds Momenta co-founder Robert S. Langer, who is leaving the board after eight years of service. Dr. Langer will continue to serve as a scientific consultant to the company following his departure from the board.
Icagen Completes Enrollment in Phase II Exercise Induced Asthma Trial
RESEARCH TRIANGLE PARK, N.C., June 12, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today reported the completion of enrollment in the Company's Phase II proof-of-concept study of senicapoc in patients with exercise induced asthma. Initial results from this study are expected during the second half of this year.